Logan Walker, APRN
Nurse Practitioner · la Vista, NENPI 1821727090
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.6%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Corcept Therapeutics at 38.0% of the total. 2025 is the largest year on record at $7,941, more than ten times the $328 reported in 2021. Among nurse practitioner clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 372 payments — averaging $49.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$7K
- Tandem Diabetes Care, Inc.$2K
- Medtronic$2K
- Bayer$1K
- Lilly USA, LLC$1K
- BETA Bionics, Inc.$821
- plus $4K from 29 others
What the payments were for
- Speaking & faculty fees$4,04022%
- Travel & lodging$4,29123%
- Food & beverage$10,05255%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 47 | $6,987 |
| Tandem Diabetes Care, Inc. | 9 | $2,191 |
| Medtronic | 25 | $2,065 |
| Bayer | 59 | $1,477 |
| Lilly USA, LLC | 59 | $1,135 |
| BETA Bionics, Inc. | 18 | $821 |
| Novo Nordisk | 51 | $715 |
| Sanofi-aventis U.S. LLC | 14 | $429 |
| AstraZeneca(2 entities) | 9 | $425 |
| Boehringer Ingelheim | 22 | $425 |
| Xeris Pharmaceuticals, Inc. | 9 | $251 |
| Chiesi USA, Inc. | 3 | $210 |
| Kyowa Kirin, Inc. | 4 | $160 |
| AbbVie | 4 | $159 |
| Amgen | 4 | $157 |
| Insulet Corporation | 2 | $96 |
| Tolmar, Inc. | 4 | $82 |
| Boston Scientific | 2 | $79 |
| Madrigal Pharmaceuticals | 3 | $69 |
| Lexicon Pharmaceuticals, Inc. | 2 | $45 |
| Ascendis Pharma Endocrinology Inc | 3 | $44 |
| Johnson & Johnson(2 entities) | 2 | $43 |
| Recordati_rare_diseases_inc. | 2 | $37 |
| Sequel Med Tech, LLC | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| LEO Pharma Inc. | 2 | $30 |
| Radius Health, Inc. | 1 | $26 |
| Astellas Pharma US Inc | 1 | $26 |
| Ascensia Diabetes Care US Inc. | 1 | $25 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
| Antares Pharma, Inc. | 1 | $23 |
| Pfizer | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Novartis | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$5,858
- t:slim X2 Insulin Pump with Control-IQ$1,999
- iLet Bionic Pancreas$1,242
- MINIMED 780G$594
- INPEN SMART INSULIN DELIVERY SYSTEM$552
- Kerendia$359
- iLet Insulin Infusion Kit Inset$291
- iLet Insulin Infusion Kit Contact Detach$291
- MINIMED 770G$174
- MOUNJARO$143
- FARXIGA$125
- LOKELMA$125
- QULIPTA$125
- UBRELVY$125
- TZIELD$119
- GVOKE HYPOPEN$110
- MYALEPT$104
- JUXTAPID$104
- MYCAPSSA$104
- CRYSVITA$102
How this compares
$18,394 in reported general payments places this provider in the 95th percentile of 924 nurse practitioner providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 537 | $641,536 |
| KorlymMifepristone | 23 | $541,123 |
| OzempicSemaglutide | 142 | $178,769 |
| Lyumjev Kwikpen U-200Insulin Lispro-Aabc | 40 | $137,831 |
| JardianceEmpagliflozin | 95 | $112,697 |
| Tresiba Flextouch U-200Insulin Degludec | 97 | $98,347 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 45 | $98,014 |
| KerendiaFinerenone | 110 | $88,878 |
| ForteoTeriparatide | 13 | $56,057 |
| TradjentaLinagliptin | 41 | $39,819 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 53 | $38,910 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 20 | $33,954 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 40 | $31,750 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $29,850 |
| FarxigaDapagliflozin Propanediol | 20 | $22,606 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Forteo, Humalog, Insulin Lispro | $1,135 | $701,217576 claims |
| Corcept TherapeuticsKorlym | $6,987 | $541,12323 claims |
| Novo NordiskOzempic, Rybelsus | $715 | $194,451156 claims |
| Boehringer IngelheimJardiance, Tradjenta | $425 | $152,515136 claims |
| BayerKerendia | $1,477 | $88,878110 claims |
| AstraZenecaFarxiga | $425 | $22,60620 claims |
| Johnson & JohnsonInvokamet | $43 | $7,85914 claims |
| AbbVieSynthroid | $159 | $5,18453 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 924 nurse practitioner providers in Nebraska.
Other nurse practitioner in la Vista
- Kristen HammesOmaha$899K
- Amy MuchowiczOmaha$78K
- Winifred SchaedelPalmyra$64K
- Kari CunninghamOmaha$53K
- Laura DonovanOmaha$49K
- Kathleen HealeyOmaha$36K
- Katie RuchOmaha$26K
- Jodi FuehrerGrand Island$25K
- Amanda GuggenmosOmaha$23K
- Lisa OstendorfLincoln$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.